Zydus Lifesciences reported its highest-ever EBITDA and margins for FY26. Consolidated PAT stood at ₹5,026.4 crore. The company also announced a share buyback of up to ₹1,100 crore at ₹1,260 per share, signaling confidence in future prospects.
Zydus Lifesciences Posts Record FY26 Performance, Announces ₹1,100 Crore Buyback
Consolidated PAT stood at ₹5,026.4 crore and Consolidated EBITDA reached ₹8,984.6 crore for FY2025-26.
Reader Takeaway: Record profitability driven by product mix and cost efficiency, offset by US generics competition risks.
What just happened
Zydus Lifesciences announced its financial results for the fiscal year 2025-26, reporting a consolidated profit after tax (PAT) of ₹5,026.4 crore. The company also achieved its highest-ever consolidated EBITDA of ₹8,984.6 crore, with an EBITDA margin of 31.2%. Additionally, the Board of Directors approved a share buyback program of up to ₹1,100 crore at a price of ₹1,260 per share.
The company's consolidated revenue for the fiscal year was ₹27,148.4 crore. Research and development (R&D) expenditure was maintained at approximately 8% of revenue, totaling ₹2,273.2 crore.
Why this matters
The record operational performance, including the highest-ever EBITDA and margins, indicates strong underlying business momentum. The share buyback signals management's confidence in the company's valuation and its commitment to returning capital to shareholders. The guidance for high-teen revenue growth in FY27 suggests expectations for continued expansion.
The backstory
Zydus Lifesciences has been focusing on strengthening its product portfolio and expanding its global presence. The company has been actively pursuing acquisitions in MedTech and consumer wellness to diversify its business. Its performance in the fiscal year reflects the successful execution of its strategies, including optimizing its product mix and improving cost efficiencies.
What changes now
With the approved buyback, Zydus Lifesciences will reduce its equity base, potentially boosting earnings per share. The company is also set to focus on integrating its recent acquisitions and delivering on its growth targets for the upcoming fiscal year. Investors will be watching the integration process and the impact of strategic diversification.
Risks to watch
The company faces inherent risks associated with the highly regulated global pharmaceutical industry. Specific concerns include potential regulatory non-compliance and pricing pressures in the competitive US generics market, which could impact profitability and operational continuity.
Peer comparison
Zydus Lifesciences operates in a competitive landscape with other large Indian pharmaceutical companies. While specific peer comparisons require detailed financial analysis, the reported EBITDA margin of 31.2% is a key indicator of its operational efficiency relative to industry benchmarks. The company's R&D spend as a percentage of revenue also places it among those prioritizing innovation.
Context metrics
- Consolidated Revenue FY2025-26: ₹27,148.4 crore
- Consolidated EBITDA FY2025-26: ₹8,984.6 crore
- Consolidated PAT FY2025-26: ₹5,026.4 crore
- Net Debt to Equity Ratio: 0.16x
- R&D Spend FY2025-26: ₹2,273.2 crore
- Share Buyback Size: Up to ₹1,100 crore
- Share Buyback Price: ₹1,260 per share
What to track next
Investors should monitor the progress of the share buyback execution, the integration of acquired businesses in MedTech and consumer wellness, and the company's ability to achieve its high-teen revenue growth guidance for FY27. Keeping an eye on regulatory developments and competitive dynamics in key markets, especially the US, will also be crucial.